# OnCo record immune-product-evidence (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/immune-product-evidence/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "immune-product-evidence" ;
  schema:name "Immune measurements and product evidence"@en ;
  schema:description "Each immune test or product-quality check answers a particular question. Connecting those questions helps explain how a proposed treatment moves from molecular measurements to evidence in people."@en ;
  schema:url <https://onco.cc/terms/immune-product-evidence/> ;
  schema:dateModified "2026-11-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1186/1471-2172-9-9>, <https://doi.org/10.1038/ncomms13404>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products> ;
  onco:related <https://onco.cc/terms/elispot/>, <https://onco.cc/terms/intracellular-cytokine-staining/>, <https://onco.cc/terms/peptide-hla-multimer-staining/>, <https://onco.cc/terms/immune-cytotoxicity-assays/>, <https://onco.cc/terms/tcr-repertoire-sequencing/>, <https://onco.cc/terms/tcr-repertoire-clonality/>, <https://onco.cc/terms/pbmc-specimens/>, <https://onco.cc/terms/binding-presentation-recognition/>, <https://onco.cc/terms/immunopeptidome/>, <https://onco.cc/terms/immunopeptidomics/>, <https://onco.cc/terms/peptide-hla-binding-prediction/>, <https://onco.cc/terms/immunodominance/>, <https://onco.cc/terms/epitope-spreading/>, <https://onco.cc/terms/self-similarity-immune-recognition/>, <https://onco.cc/terms/immunogenicity-versus-efficacy/>, <https://onco.cc/terms/tissue-preparation-assay-fit/>, <https://onco.cc/terms/finite-tissue-budget/>, <https://onco.cc/terms/rna-integrity/>, <https://onco.cc/terms/specimen-provenance/>, <https://onco.cc/terms/mrna-construct-anatomy/>, <https://onco.cc/terms/codon-optimization/>, <https://onco.cc/terms/modified-rna-nucleosides/>, <https://onco.cc/terms/in-vitro-transcription/>, <https://onco.cc/terms/dsrna-impurities/>, <https://onco.cc/terms/multi-epitope-constructs/>, <https://onco.cc/terms/binder-targeting-module/>, <https://onco.cc/terms/binder-affinity-epitope-developability/>, <https://onco.cc/terms/binder-format-constraints/>, <https://onco.cc/terms/scfv-vhh-formats/>, <https://onco.cc/terms/delivery-target-versus-therapeutic-target/>, <https://onco.cc/terms/chemistry-manufacturing-controls/>, <https://onco.cc/terms/certificate-of-analysis/>, <https://onco.cc/terms/manufacturing-process-comparability/>, <https://onco.cc/terms/cell-segmentation/>, <https://onco.cc/terms/targeted-proteomics-quantification/> .
